The startup operates a gene therapy platform that utilizes artificial intelligence and big data for promoter and capsid engineering, along with mechanical modeling, to develop efficient and cost-effective treatments. It focuses on providing targeted gene therapies for rare and incurable diseases, enhancing the healthcare sector's ability to deliver optimal therapeutic solutions.

This startup develops three-dimensional printing materials, including filaments, resins, and powders, specifically for dental applications such as clear aligners and permanent tooth restorations. Their technology addresses the limitations in the global orthodontic market by providing high-quality, UV-curable materials that enhance dental health outcomes.

LISCure Biosciences develops bacteria-mediated immunotherapy that enhances the immune response specifically within tumor microenvironments to improve cancer treatment efficacy. This approach aims to increase patient outcomes by targeting and disrupting the mechanisms that allow cancer cells to evade immune detection.

NextBio utilizes organoid technology and molecular diagnostics to create personalized medicine solutions for researchers and consumers. This approach enables precise drug testing and tailored treatment plans, addressing the limitations of traditional one-size-fits-all medical therapies.